文献速递泌尿生殖MRUS

开发基于PI-RADS v2的新型列线图预测高级别前列腺癌

Developing a new PI-RADS v2-based nomogram for forecasting high-grade prostate cancer.
PubMed 文献 · Clin Radiol · 2017-01-06

研究基于PI-RADS v2、MRI前列腺体积、调整PSA密度等参数建立预测高级别前列腺癌的列线图,训练队列158例,验证队列89例。多因素分析显示年龄、PI-RADS v2评分和调整PSAD为独立预测因子,模型截断值0.33,训练队列敏感度83.3%、特异度87.4%,验证队列AUC=0.83。结论认为该列线图有效,可能减少不必要穿刺和过度诊断。

要点

  • 年龄、PI-RADS v2评分和调整PSAD是高级别前列腺癌的独立预测因子。
  • 列线图模型截断值0.33,训练队列敏感度83.3%、特异度87.4%。
  • 验证队列AUC=0.83,诊断性能与训练队列相似。

核心结论

  • 基于PI-RADS v2、MRI前列腺体积和调整PSAD的列线图能有效预测高级别前列腺癌,可能减少不必要的前列腺穿刺和过度诊断。

研究设计与样本

  • 预测模型研究,训练队列为2014年8月至2015年8月间158例适合分析的活检初治男性,验证队列为2015年9月至2016年3月间89例;采用向后逻辑回归建立模型并绘制列线图;所有病灶均经MRI引导下经直肠超声靶向和分区穿刺获得组织学。

诊断标准与关键数值

  • 多因素分析显示年龄、PI-RADS v2评分和调整PSAD为高级别前列腺癌的独立预测因子;逻辑回归模型最具鉴别力的截断值为0.33,训练队列敏感度83.3%、特异度87.4%、阳性预测值88.4%、阴性预测值81.2%;验证队列AUC=0.83。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To establish a predictive nomogram for high-grade prostate cancer (HGPCa) in biopsy-naive patients based on the Prostate Imaging-Reporting and Data System version 2 (PI-RADS v2), magnetic resonance imaging (MRI)-based prostate volume (PV), MRI-based PV-adjusted prostate-specific antigen density (PSAD), and other classical parameters.

MATERIAL AND METHODS: Between August 2014 and August 2015, 158 men who were eligible for analysis were included as the training cohort. A prediction model for HGPCa was built using backward logistic regression and was presented on a nomogram. The prediction model was evaluated by a validation cohort between September 2015 and March 2016 (n=89). Histology of all lesions was obtained with MRI-directed transrectal ultrasound (TRUS)-guided targeted and sectoral biopsy.

RESULTS: The multivariate analysis revealed that patient age, PI-RADS v2 score, and adjusted PSAD were independent predictors for HGPCa. The most discriminative cut-off value for the logistic regression model was 0.33; the sensitivity, specificity, positive predictive value, and negative predictive value were 83.3%, 87.4%, 88.4%, and 81.2%, respectively. The diagnostic performance measures retained similar values in the validation cohort (AUC=0.83).

CONCLUSION: The nomogram for forecasting HGPCa is effective and potentially reducing harm from unnecessary prostate biopsy and over-diagnosis.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Niu XK, He WF, Zhang Y, et al. Developing a new PI-RADS v2-based nomogram for forecasting high-grade prostate cancer. Clin Radiol. 2017. PMID: 28069159. doi:10.1016/j.crad.2016.12.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。